Revolve Wealth Partners LLC Has $391,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Revolve Wealth Partners LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 3,487 shares of the biopharmaceutical company’s stock after buying an additional 196 shares during the period. Revolve Wealth Partners LLC’s holdings in Gilead Sciences were worth $391,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Charter Oak Capital Management LLC acquired a new position in shares of Gilead Sciences during the 1st quarter worth approximately $216,000. Wedmont Private Capital grew its position in shares of Gilead Sciences by 20.6% during the 1st quarter. Wedmont Private Capital now owns 16,259 shares of the biopharmaceutical company’s stock worth $1,685,000 after purchasing an additional 2,778 shares in the last quarter. Sivia Capital Partners LLC grew its position in shares of Gilead Sciences by 7.9% during the 1st quarter. Sivia Capital Partners LLC now owns 3,580 shares of the biopharmaceutical company’s stock worth $401,000 after purchasing an additional 262 shares in the last quarter. Perkins Coie Trust Co grew its position in shares of Gilead Sciences by 2.6% during the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock worth $435,000 after purchasing an additional 100 shares in the last quarter. Finally, Piscataqua Savings Bank grew its position in shares of Gilead Sciences by 1.8% during the 1st quarter. Piscataqua Savings Bank now owns 6,904 shares of the biopharmaceutical company’s stock worth $774,000 after purchasing an additional 120 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $112.46 on Friday. The company has a fifty day moving average price of $105.39 and a 200-day moving average price of $101.56. The company has a market capitalization of $139.89 billion, a P/E ratio of 303.95, a PEG ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 52-week low of $62.69 and a 52-week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter last year, the firm earned ($1.32) earnings per share. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.81%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 66.53%.

Analysts Set New Price Targets

Several research firms recently issued reports on GILD. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research report on Thursday, February 13th. Finally, BMO Capital Markets increased their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares in the company, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the sale, the chief financial officer now owns 168,174 shares of the company’s stock, valued at approximately $17,893,713.60. This trade represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 60,929 shares of company stock worth $6,748,980 over the last three months. 0.27% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.